Roche Forecast, price target & analysts
Roche Target price 2025 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Price Target
| Target Price | CHF301.90 |
| Price | CHF270.20 |
| Potential | 11.73% |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF301.90. This is 11.73% higher than the current stock price. The highest price target is CHF438.00 62.10% , the lowest is CHF230.00 14.88% . | |
| A rating was issued by 22 analysts: 9 Analysts recommend Roche to buy, 9 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 11.73% . Most analysts recommend the Roche stock at Buy or hold. |
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 58.72 | 60.82 |
| 7.21% | 3.58% | |
| EBITDA Margin | 33.76% | 38.36% |
| 2.89% | 13.62% | |
| Net Margin | 19.53% | 21.37% |
| 0.14% | 9.44% |
18 Analysts have issued a sales forecast Roche 2024 . The average Roche sales estimate is CHF60.8b . This is 3.46% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF63.3b 7.73% , the lowest is CHF60.0b 2.11% .
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | CHF58.7b | 7.21% |
|---|---|---|
| 2024 | CHF60.8b | 3.58% |
| 2025 | CHF64.8b | 6.52% |
| 2026 | CHF67.6b | 4.38% |
| 2027 | CHF70.7b | 4.53% |
| 2028 | CHF72.9b | 3.08% |
16 Analysts have issued an Roche EBITDA forecast 2024. The average Roche EBITDA estimate is CHF23.3b . This is 17.58% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF25.9b 30.61% , the lowest is CHF20.7b 4.10% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2023 | CHF19.8b | 9.89% |
|---|---|---|
| 2024 | CHF23.3b | 17.70% |
| 2025 | CHF25.4b | 9.04% |
| 2026 | CHF26.8b | 5.16% |
| 2027 | CHF27.9b | 4.41% |
| 2028 | CHF28.8b | 3.03% |
EBITDA Margin
| 2023 | 33.76% | 2.89% |
|---|---|---|
| 2024 | 38.36% | 13.62% |
| 2025 | 39.27% | 2.37% |
| 2026 | 39.56% | 0.74% |
| 2027 | 39.51% | 0.13% |
| 2028 | 39.49% | 0.05% |
14 Roche Analysts have issued a net profit forecast 2024. The average Roche net profit estimate is CHF13.0b . This is 22.47% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF15.0b 41.17% , the lowest is CHF11.7b 10.29% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2023 | CHF11.5b | 7.34% |
|---|---|---|
| 2024 | CHF13.0b | 13.37% |
| 2025 | CHF15.0b | 15.77% |
| 2026 | CHF16.3b | 8.64% |
| 2027 | CHF17.3b | 5.67% |
| 2028 | CHF18.4b | 6.38% |
Net Margin
| 2023 | 19.53% | 0.14% |
|---|---|---|
| 2024 | 21.37% | 9.44% |
| 2025 | 23.23% | 8.70% |
| 2026 | 24.18% | 4.09% |
| 2027 | 24.44% | 1.08% |
| 2028 | 25.22% | 3.19% |
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 14.39 | 16.31 |
| 7.34% | 13.34% | |
| P/E | 16.56 | |
| EV/Sales | 4.03 |
14 Analysts have issued a Roche forecast for earnings per share. The average Roche <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is CHF16.31 . This is 22.45% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is CHF18.80 41.14% , the lowest is CHF14.69 10.29% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2023 | CHF14.39 | 7.34% |
|---|---|---|
| 2024 | CHF16.31 | 13.34% |
| 2025 | CHF18.89 | 15.82% |
| 2026 | CHF20.52 | 8.63% |
| 2027 | CHF21.68 | 5.65% |
| 2028 | CHF23.07 | 6.41% |
P/E ratio
| Current | 20.28 | 13.80% |
|---|---|---|
| 2024 | 16.56 | 18.34% |
| 2025 | 14.31 | 13.59% |
| 2026 | 13.17 | 7.97% |
| 2027 | 12.46 | 5.39% |
| 2028 | 11.71 | 6.02% |
Based on analysts' sales estimates for 2024, the Roche stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.03 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.54 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.17 | 16.81% |
|---|---|---|
| 2024 | 4.03 | 3.46% |
| 2025 | 3.78 | 6.12% |
| 2026 | 3.62 | 4.20% |
| 2027 | 3.46 | 4.34% |
| 2028 | 3.36 | 2.99% |
P/S ratio
| Current | 3.66 | 14.15% |
|---|---|---|
| 2024 | 3.54 | 3.35% |
| 2025 | 3.32 | 6.12% |
| 2026 | 3.18 | 4.20% |
| 2027 | 3.05 | 4.33% |
| 2028 | 2.95 | 2.99% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
